Nanostics develops ClarityDX Prostate, a diagnostic test that utilizes clinical features and blood-based biomarkers to assess the risk of aggressive prostate cancer. This technology reduces the need for invasive prostate biopsies, enabling patients and healthcare providers to make more informed decisions regarding cancer screening.
Funding
$17.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for prostate cancer screening, such as Prostate-Specific Antigen (PSA) tests, often lead to unnecessary biopsies due to their limited accuracy in distinguishing between aggressive and indolent forms of the disease. These biopsies are invasive, uncomfortable, carry risks, and contribute to significant healthcare costs.
Solution
Nanostics offers ClarityDX Prostate, a diagnostic test that leverages clinical data and blood-based biomarkers to more accurately assess a patient's risk of having aggressive prostate cancer. The ClarityDX platform combines machine learning with data from proprietary biomarkers found on extracellular vesicles in blood. By analyzing these biomarkers in conjunction with clinical information, ClarityDX Prostate provides a risk score that helps patients and healthcare providers make more informed decisions about whether a biopsy is necessary, potentially reducing the number of unnecessary procedures and associated hospitalizations. The test can be used both for initial diagnosis and for monitoring patients on active surveillance.
Target Audience
The primary audience includes urologists, oncologists, and primary care physicians involved in prostate cancer screening and diagnosis, as well as patients who are considering or undergoing prostate cancer screening or active surveillance.
Features
- Combines clinical features and blood-based biomarkers for risk assessment
- Utilizes proprietary biomarkers found on extracellular vesicles (EVs)
- Employs microflow cytometry to quantify EV size, concentration, and marker abundance
- Advanced machine learning algorithms analyze biomarker and clinical datasets
- Provides an Area Under the Curve (AUC) of >0.82 for identifying clinically significant prostate cancer
- Offers high sensitivity (95%) and negative predictive value (91%)
- Designed to reduce unnecessary biopsies and related hospitalizations